Moderate-to-severe Plaque Psoriasis Clinical Trial
Official title:
Safety, Tolerability and Pharmacokinetics Studies Following Multiple Subcutaneous Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
This is a multiple dose escalating and open labeled clinical trial to evaluate the safety,
tolerability, and pharmacokinetics (PK) of multiple subcutaneous (s.c.) injections of
SHR-1314 in adults with moderate-to-severe plaque psoriasis.
The primary objective of this study is to investigate the safety and tolerability of multiple
doses of subcutaneous SHR-1314 in subjects with moderate-to-severe plaque psoriasis.
Secondary objectives are to determine the pharmacokinetics (PK) and immunogenicity profile of
SHR-1314 in subjects with moderate-to-severe plaque psoriasis.
16 subjects with 2 dose groups will be enrolled in the study, all of whom received the SHR-1314 without placebo control. There are 8 subjects in each cohort. The dose will be started at 160mg and will be escalated by following dose escalating rules. The primary endpoint is the safety and tolerability : adverse events, vital signs, physical examination, laboratory examination, 12 lead electrocardiogram, injection site reactions, etc. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05787236 -
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
|
||
| Active, not recruiting |
NCT04612699 -
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06258668 -
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
|
||
| Recruiting |
NCT06142357 -
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
|
||
| Completed |
NCT06182384 -
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
|
Phase 1 | |
| Not yet recruiting |
NCT04839016 -
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
|
Phase 3 |